Highlights of the Annual Dialysis Conference: Chronic Kidney Disease Related-Anemia

February 18-20, 2007; Denver, Colorado

Anne G. Le, PharmD, RPh

Disclosures

April 02, 2007

In This Article

Switching From Epoetin to Darbepoetin Alfa: Impact on Anemia Management

Francis Dumler, from William Beaumont Hospital, in Royal Oak, Michigan,[8] presented the results of the impact of a Formulary switch from epoetin alfa to darbepoetin alfa on hemoglobin concentration in chronic hemodialysis patients. This was a prospective, longitudinal, observational study of 54 patients (mean age: 61 ± 16 years; 47% female; 30% black; 40% diabetics) treated by a single nephrologist. Median values for the quarter preceding the switch (PRE) were compared to the subsequent 3 months starting 30 days after the conversion (POST). Epoetin was administered intravenously 3 times/week and darbepoetin was administered intravenously once weekly. Results are shown in the table .

In addition, the median epoetin dose during the PRE period was 12,000 U/week and the median dabepoetin dose during the POST period was 60 mcg vs the package insert suggestion of 40 mcg/week. The conversion to darbepoetin alfa was performed according to the manufacturer's recommendation in the package insert, but because hemoglobin values fell 7%, the dosages had to be increased. In conclusion, conversion to IV darbepoetin should be calculated as 1 mcg per 200 U of epoetin.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....